Lucid Diagnostics tumbles on stock offering unveil

Shares of Lucid Diagnostics LUCD.O down ~25% to $1.24 in extended trading on equity raise plans

New York-based commercial-stage subsidiary of PAVmed Inc PAVM.O announces stock offering without disclosing deal size

With ~90.75 mln shares outstanding, co has about $150 mln market cap

Stock on Weds finished up 1.9% at $1.65. Shares ended 2024 at 82 cents

Canaccord Genuity sole bookrunner for proposed offering

Lucid says it's focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer